of a biomarker to correctly detect the disease status can be defined as sensitivity (i.e., true positive rate) and specificity (i.e., true negative rate). 1 The subject is labeled as diseased when the measurement of specific biomarker becomes greater than the TLV. The Biomarker specific TLV is required to be established for disease status detection. An important field of research serves literature with several methodologies of Bivariate and Multivariate distributions through marginal and conditional distributions. [2] [3] [4] [5] 7 Different form of Bivariate Beta distributions have been proposed in the statistics literature. 6, 7, 9, 10, 27 The application of Univariate and Bivariate Beta distributions are widely adopted in different fields. These are found suitable in population genetics, linkage analysis and drought intensity data analysis. [11] [12] [13] These are used to find out the proportions of diseased second premolars and molars in dentistry and estimation of tree diameter in forestry and for retinal image recognition measurements. [14] [15] [16] The joint density function of Bivariate Beta distribution is applied to explore the readership of two monthly magazines. 17 Recently the different class of Beta distributions are explored and has received a growing interest. 18, 19 It is one of the most widely adopted distribution in experimental research. [20] [21] [22] Univariate Beta-distribution is easy to implement. It can be applied through standard Gammadistribution. 23, 24 However, work with pairs of correlated beta-distribution is difficult to conduct due to non-availability of the multivariate form of the univariate Beta distribution. 24 The marginal distribution functions and prior knowledge about a measurement of association are suitable to deal with such problems. 25 Although it is limited with near normal and weakly correlated Beta distributions. 24 The algorithm for generating data from bivariate Beta random variables has been attempted through three parameters. 26 The generation of data on correlated bivariate Beta-distributed has been explored through mixture distribution approach. 28 The gene-biomarker expression values on prostate cancer patients are considered as diagnosis marker for illustration of correlated Beta Bivariate distribution. 27, 29, 30, 32 The proposed method is performed through MCMC technique to discriminate the TLV of gene -biomarker expressions among healthy and diseased individual. The specific Bivariate Beta distributions are studied and finally some empirical applications with gene-biomarker expression data are presented to obtain the TLV.
MATERIAL AND METHODS

INITIAL ASSUMPTION
A Beta distribution is assumed with parameter p and other known parameters α and β. The random number is assumed with k times of 'successes' that is drawn from a binomial distribution (likelihood) with parameters p and v. In next step a random draw p is attempted from a Beta-distribution with parameters p + k and β+v-k to obtain the paired Beta-distributed random variables. The specified correlation v × (v + α + β) is utilized to generate the paired Beta-distribution. The estimation of p1 and p2 were obtained through determination ofα;β; k and v respectively.
BIVARIATE BETA DISTRIBUTION
Suppose the gamma variates G , G , G are independent having parameters α , β , α , β , and α , β respectively. Then the joint density is obtained from
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Is the generalized beta function. When λ / = 1, the density (2) reduces to a Bivariate Beta distribution with parameters by:
The correlation coefficient between X and Y is range from In this context, bivariate Beta distributions with five independent gamma variates[G , G , G < , G andG > ]
and common scale parameter 1 is defined by Arnold and Ng 3 and it is considered as It is defined as
This joint density is free from closed form and can be calculated numerically. In this work, we applied the correlation structure through consideration of δ. The value of δ finalized with simulation. These random variables have distributions which are usually called Beta distribution of the second kind. The joint probability density
is readily verified to be of the form:
Therefore, the joint p.d.f of (V,W) is obtained as
CORRELATION BETWEEN BIVARIATE BETA DISTRIBUTIONS 
It is defined as
where the random variable f( )is distributed with standard Gamma distribution with parameters and 1 f\[( ; 1) . Further the independent random variable f( ) is a standard Gamma distribution having parameters and 1 f\[( ; 1) .
It is defined as g(` ) = h = /( + )and g(` ) = h = /( + ) .
respectively.
The correlated random variable is handled through shared random variable technique, that further extended with correlated binary variables. 31, 33 Let the sum of two independent random standard Gamma variables is called as f(
is distributed with f\[( * + l , 1). 34, 35 Now, 
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The terms l and l are linked with , , and as * + l = , * + l = , * + l = ,and * + l = , respectively for the marginal distributions of ` and ` . 35 The covariance (n oo ) between ` and ` is approximated with first-ordered Taylor series through
where, E denotes the expected value operator. The simplified form of this expression is
The terms k r and k r are estimated through k r = n oo × (1 + + ) × s 
DATA METHODOLOGY
The proposed extensions of the bivariate Beta distribution model was applied to real data set, publicly available in the GEO(Gene Expression Omnibus) database. The GEO accession number of the data set is GDS4824. A total of 21 samples (13 prostate cancer patients and 8 normal individuals) are considered in this study. The study was about gene expression of malignant and benign stage of prostate tissues. It provides insight about gene expression signature for prostate cancer. The objective of the primary study was the Identification of novel biomarkers and immunotherapy targets for prostate cancer (PCa) is crucial to better diagnosis and therapy. The library ("limma") in R (open source software) is used to explore and tabled the most significant genes ID. 36 Initially, all gene expression changes among cancer and normal individuals are observed and given in Figure 1 through Heatmap representation. It has been observed through colors that few genes were expressed significantly different between malignant and benign tissues. Thereafter significant level cut off the value of p=0.05 is considered to be labeled the most differently expressed genes and that are given in Figure 2 . In next step, a significant level was decided with $p=0.001$ is selected to detect the genes those expressions were highly different between malignant and benign tissues. It has been observed only genes ( Figure 3 ) were differently expressed malignant and benign tissues. Only Two genes from there i.e (gene ID with 209426 and 207147), were considered in this study for computation simplicity and AUC estimation.
BAYESIAN ANALYSIS
Suppose the pair of independent random variables areu v and u v .It is assumed that . The prior distribution of the parameters h and h are from (4) with ( , , < , = , > ) and where
where 0 < h < 1,0 < h < 1
The expected value of posteriors of h and h are obtained through g(h ) = ‰ ‰ h ‚(h , h |u =^ , u =^ )‹h ‹h OE OE (18) and
The random variables are obtained from ‚ ƒ ,ƒ (h , h ) for specified prior values of ( , , < , = , > ), Y = 1,2, … . . [. and thereafter it approximated with integrals by
The 100(1 − ")% highest posterior density (HPD) interval for the parameter h , (• , -) is obtained for the parameters through
and
The Monte Carlo integration is used with interval (0,1) to approximate the values of U and L .
The estimation for p is obtained through 100(1 − γ)% highest posterior density (HPD) interval. Similarly, for p the HPD is obtained through 100(1 − γ)%. Initial data of (p , p ) are obtained from
In next step it is used to generate values of K , K ),say (k , k ). The Monte Carlo simulation is used to evaluate the parameters 20,000 simulations are used for each setting with sample size n=50 and 100. The simulated biases and mean squared errors (MSEs) of the estimators are presented in Table 2 and Table 3 for two representative sets of parameter (α , α , α < , α = , α > ) =(1,1.5,2,2.5,3) and (1,1.5,2,2.5,3), respectively. It is to be noted that the biases and MSEs decrease when the sample size increases.
ROC ANALYSIS
Sometimes two biomarkers may be highly associated with the presence of disease and it is indispensable to consider both the biomarkers for detecting the disease status. 38 Let (` ,` ) be two sets of related biomarkers taken from a healthy group and let (ž , ž ) be two sets of biomarkers value taken from disease subjects. A particular subject is identified as disease when the values of ž and ž are large enough. 38 The CDF for healthy and disease population are defined by Further, it is assumed that Ÿ o (b , b )~a_( , ) and Ÿ ¢ (b , b )~a_( , ) . The estimation procedure for parameters above is obtained from mean and variance of Beta distribution for each sample. The mean and variance observed separately disease and not disease individuals. The moment approach is easy to use for the iterative solution for the maximum likelihood estimates. It is assumed for the disease individual, the mean is standard deviations is σ $ . Similarly, from the sample data in normal individual, the mean p £ and standard deviations is σ 8 respectively, the estimates of the parameters is
The AUC of bivariate beta ROC curve takes the following form:
113 The explicit form of FPR and TPR in case of bivariate setting is analytically complicated. The FPR from a bivariate biomarker at the thresholds t and t are defined for TLVs for respective biomarkers. The FPR and TPR is presented through Beta distribution.
Let the density function X is defined as
The term B(.) provides a normalization constant that equals to d and e for equations with the interval [0,1]. 27 Now subscripts of ( , ) and ( , ) are presented as ( , ) respectively. Integrating over the equation from 0 to b gives the following Ÿ °= ,
Similarly, the equation (28) provides biomarkers. The estimated value of •-ś is observed with 95% credible intervals are presented in Table  9 . Based on simulated data the ROC curves are generated (Figure 1, 2) .
RESULT
A total of 20,000 separate iterations is performed to obtain the estimates of •-ś . The SD,95% HPD and MC error for •-s of bivariate beta ROC curve are presented in Table 9 .From Table 1 -8, we found that then is reversely proportional between biomarkers. It may be the due present correlation between biomarker is negligible or X and Y are independent. The program to generate AUC has been performed in OpenBUGS. The convergence of parameters has been observed with trace plots obtained from OpenBUGS outputs. For example Table 9 shows that for = 1, = 2, = 2, = 2, the posterior mean estimates of AUC is 0.83 with credible interval (0.81,0.86).The SD is observed with 0.03. From Table 9 , we observe that as the estimated parametric values deviate more among each other especially AUC decreases with incline value of . 
DISCUSSION
It is a tedious job to handle with multiple diagnostic biomarkers to take the decision about diagnosis and management of a disease. The challenge is to provide the comprehensive conclusion about disease status and stage to the treated patients in the presence of multiple biomarkers through TLV. In this paper, we have proposed the method of diagnostic decision about two correlated randomly selected biomarkers. The parametric distribution is adopted to calculate the diagnostic accuracy of bivariate beta distributed biomarkers. The method is proposed for combining the biomarkers to predict the accuracy. We emphasized the application of Beta distribution over normal distribution because the range of normal distribution is (−∞, ∞).Bivariate Beta distributions are widely adopted in different applications. It is most suitable to be assumed as a prior distribution for the correlated binomial variable in Bayesian setup. 39 The prior information of two correlated random variables applied in clinical trials. 40 ,41
CONCLUSION
The above-mentioned applications are not appropriate for positively correlated random variables. However in real life, it may not be possible to get only positively correlated random variables. In a 117 clinical setting, most of the biomarkers do not take any infinite values. The limited range of maximum and minimum values of biomarkers can be standardized into 0 to 1 scale range. In this scenario, Beta distribution is suitable enough to handle with biomarker than normal distribution as the parametric choice. It is also difficult to get a large number of the sample size of multiple biomarker measurements in any clinical setting due to cost and ethical issues. Hence, it is appropriate to assume Beta distribution than the normal distribution.
The characteristics of the proposed method have also been observed through changes of different correlation measurement and changes of parametric values. The MCMC iteration method is used to explore the approximate value of AUĆ. The proposed method is illustrated with a real-life example of prostate cancer data set.
The bivariate beta ROC model is applied to obtain the relation between FPR and TPR. The optimum value of bivariate Beta distribution on example data is obtained through estimates of AUC on combine accuracy of the two biomarkers together. The simulation studies have been conducted to obtain the estimates of different correlation coefficient starting from 0 to 0.9. It is assumed that individual is diseased when the values of Y and Y are large enough. The bivariate ROC curve for each biomarker plotted separately and it is concluded that the bivariate beta ROC model can be applied once the data fit the bivariate Beta distribution. 
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